In this study, we showed that FSP1 is overexpressed in KEAP1 mutant lung cancers and that FSP1 is required for xenograft tumor growth in KEAP1 deficient lung cancers, further nominating FSP1 as a promising therapeutic target for treating KEAP1 deficient lung cancers (Fig. 7c). This evidence concerns the gene AIFM2 and lung carcinoma.